For obvious reasons, supply chains involving the Life Sciences come with a few dicey extra variables. Trevor Miles writes for 21st Century Supply Chain about seven processes that are best executed with an integrated approach.
The Lucky 7 Processes
- Collaborative launch management – clinical, regulatory and commercial
- Jurisdictional control to respect regulatory needs during planning
- Consensus demand planning across affiliates and countries
- Risk evaluation and recovery to deal with shortages and FDA shutdowns
- Shortage analysis and reporting for FDASIA compliance
- Supply and capacity planning to balance demand across regions
- Expiry management to balance long supply lead times and shifting demand
Miles goes into depth about each of these processes in the full article. For example, for risk evaluation and recovery he has to say:
Current technical architectures do not provide the capabilities needed to address new requirements under FDASIA ̶ reporting obligations for drug shortage issues and more active inspection of production facilities for instance. Information flow is typically limited to EDI exchanges with little or no ability to understand, for example, the impact of an API supply de-commit on future treatment —drug or device— availability in a regulatory region. To do this, Life Sciences companies will require much greater visibility and what-if scenario capabilities to both inspect and affect the global supply chain across Third Party Operators and into the supply base.
If you can navigate his dense sentence structure, there is a wealth of insights to be found. You can read his original article here: http://blog.kinaxis.com/2014/04/7-life-sciences-supply-chain-processes-require-integrated-approach/